{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:21:47Z","timestamp":1792182107744,"version":"4.4.0"},"reference-count":30,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin B.V.","award":["8224-41473"],"award-info":[{"award-number":["8224-41473"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Little is known about the impact of MF on quality of life (QoL) in newly diagnosed patients. Objectives: To describe the impact of the MF diagnosis on QoL, patient expectations, and treatment satisfaction over the first 6 months after diagnosis. Methods: Outcomes of this prospective cohort study of newly diagnosed MF patients conducted between 2020 and 2022 at the Leiden University Medical Center included the Skindex-29, RAND-12 Health Survey, degree of itch, pain, and fatigue (Visual Analogue Scale (VAS)), patient expectations, and Client Satisfaction Questionnaire-8 (CSQ-8), measured at baseline and after six months. Results: A total of 28 patients with MF were included. At baseline, 66% (n = 18) \u201cstrongly-totally\u201d expected positive effects of the treatment. At the time of diagnosis, 28% of the patients (n = 8) were moderately to severely affected. There was no statistical change in the Skindex-29 score sum score (20 [10\u201334] vs. 20 [9\u201336]; p = 0.81) or in the other three subdomains, the RAND-12 scores, and the VAS itch, pain, and fatigue over time. Treatment satisfaction was high overall. Conclusion: Despite that the newly diagnosed MF patients anticipate a positive treatment effect, few improvements in QoL and symptom reduction were found. These data can be used for adequate expectation management and provide a rationale for further evaluation of treatment regimens in these patients.<\/jats:p>","DOI":"10.3390\/cancers16050937","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T11:31:21Z","timestamp":1708947081000},"page":"937","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of Quality of Life and Treatment Satisfaction in Newly Diagnosed Cutaneous T-Cell Lymphoma Patients"],"prefix":"10.3390","volume":"16","author":[{"given":"Rosanne","family":"Ottevanger","sequence":"first","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"van Beugen","sequence":"additional","affiliation":[{"name":"Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, 2311 EZ Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette M.","family":"Kersten","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea W. M.","family":"Evers","sequence":"additional","affiliation":[{"name":"Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, 2311 EZ Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4613","authenticated-orcid":false,"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-7616","authenticated-orcid":false,"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen D.","family":"Quint","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/his.12371","article-title":"Aggressive epidermotropic cutaneous CD8+ lymphoma: A cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop","volume":"67","author":"Robson","year":"2015","journal-title":"Histopathology"},{"key":"ref_3","first-page":"241","article-title":"Plaque stage folliculotropic mycosis fungoides: Histopathologic features and prognostic factors in a series of 40 patients","volume":"47","author":"Jansen","year":"2019","journal-title":"J. Cutan. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjd.20048","article-title":"Incidence of mycosis fungoides and S\u00e9zary syndrome in the Netherlands between 2000 and 2020","volume":"185","author":"Ottevanger","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/jdv.17570","article-title":"Quality of life in patients with Mycosis Fungoides and S\u00e9zary Syndrome: A systematic review of the literature","volume":"35","author":"Ottevanger","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","article-title":"Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator","volume":"9","author":"Ottevanger","year":"2022","journal-title":"JAAD Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-4632.2011.05188.x","article-title":"Prevalence and severity of pruritus in cutaneous T cell lymphoma","volume":"51","author":"Vij","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jdv.16021","article-title":"Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and S\u00e9zary syndrome: Comparison of generic and dermatology-specific instruments","volume":"34","author":"Herbosa","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.141.3.325","article-title":"Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma","volume":"141","author":"Demierre","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13922","DOI":"10.1111\/dth.13922","article-title":"Psychiatric Comorbidity, Depression and Anxiety Levels and Quality of Life of the Patients with Mycosis Fungoides","volume":"33","author":"Engin","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1046\/j.1468-3083.2003.00823.x","article-title":"Physical and mental health survey of 20 patients with S\u00e9zary syndrome using the Medical Outcomes Study 36-Item Short-Form Health Survey","volume":"17","author":"Bouwhuis","year":"2003","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","first-page":"190","article-title":"Health-related quality of life and economic implications of cutaneous T-cell lymphoma","volume":"182","author":"Semenov","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2133.2008.08992.x","article-title":"Quality of life and psychological distress in patients with cutaneous lymphoma","volume":"160","author":"Sampogna","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/bjd.18089","article-title":"Characteristics associated with significantly worse quality of life in mycosis fungoides\/S\u00e9zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study","volume":"182","author":"Molloy","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1002\/ski2.300","article-title":"Unveiling the hidden struggles: Exploring the profound impact of advanced stage cutaneous T-cell lymphoma on quality of life","volume":"3","author":"Ottevanger","year":"2023","journal-title":"Ski. Health Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.19252","article-title":"Treatment of early-stage mycosis fungoides: Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study","volume":"184","author":"Quaglino","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ottevanger, R., van Beugen, S., Evers, A.W.M., Willemze, R., Vermeer, M.H., and Quint, K.D. (2022). Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider. Cancers, 15.","DOI":"10.3390\/cancers15010032"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of skindex, a quality-of-life instrument for patients with skin diseases","volume":"133","author":"Chren","year":"1997","journal-title":"Arch. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/jid.2011.138","article-title":"Interpretation of skindex-29 scores: Cutoffs for mild, moderate, and severe impairment of health-related quality of life","volume":"131","author":"Prinsen","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/07853890109002089","article-title":"The RAND-36 measure of health-related quality of life","volume":"33","author":"Hays","year":"2001","journal-title":"Ann. Med."},{"key":"ref_22","first-page":"101","article-title":"The Impact of Chronic Skin Disease on Daily Life (ISDL): A generic and dermatology-specific health instrument","volume":"158","author":"Evers","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0149-7189(82)90074-X","article-title":"The client satisfaction questionnaire: Psychometric properties and correlations with service utilization and psychotherapy outcome","volume":"5","author":"Attkisson","year":"1982","journal-title":"Eval. Program Plan."},{"key":"ref_24","first-page":"251","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"82","author":"Altman","year":"2008","journal-title":"Rev. Esp. Salud Public"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.17117","article-title":"The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma","volume":"192","author":"Scarisbrick","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2340\/00015555-2819","article-title":"Patients\u2019 Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas","volume":"98","author":"Porkert","year":"2018","journal-title":"Acta Derm.-Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjd.12644","article-title":"What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence","volume":"170","author":"Beynon","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12955-017-0765-y","article-title":"The effectiveness of integrated care interventions in improving patient quality of life (QoL) for patients with chronic conditions. An overview of the systematic review evidence","volume":"15","author":"Flanagan","year":"2017","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_29","first-page":"191","article-title":"Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: A clinicopathologic and follow-up study of 51 patients","volume":"138","author":"Scheffer","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00403-017-1744-1","article-title":"Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides","volume":"309","author":"Wieser","year":"2017","journal-title":"Arch. Dermatol. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/937\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:57Z","timestamp":1760105097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16050937"],"URL":"https:\/\/doi.org\/10.3390\/cancers16050937","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}